Hyperfine (HYPR) Liabilities and Shareholders Equity (2020 - 2026)
Hyperfine's (HYPR) quarterly Liabilities and Shareholders Equity came in at $60.3 million in Q1 2026, up 13.04% YoY from $53.4 million in Q1 2025, and up 9.19% on a QoQ basis from $55.3 million in Q4 2025.
Hyperfine (HYPR) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Hyperfine (HYPR) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $60.3 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 13.04% year-over-year to $60.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $202.3 million (down 21.65% YoY) and the FY2025 annual result came in at $55.3 million, down 6.18% from the prior year.
- Liabilities and Shareholders Equity improved to $60.3 million in Q1 2026, from $55.3 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $178.8 million in Q1 2022 to a low of $41.5 million in Q3 2025.
- A 5-year average of $94.2 million and a median of $85.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity sank 40.96% — and 2026, when it increased 13.04%.
- Tracing HYPR's Liabilities and Shareholders Equity over 5 years: stood at $134.1 million in 2022, then retreated by 29.73% to $94.2 million in 2023, then sank by 37.47% to $58.9 million in 2024, then decreased by 6.18% to $55.3 million in 2025, then climbed by 9.19% to $60.3 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $60.3 million (Q1 2026), $55.3 million (Q4 2025), and $41.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Hyperfine | 89.83 Mn | 45.06 Mn | 1.98 Mn | 63.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.00 Mn |
| Mar 31, 2026 | 60.34 Mn |
| Dec 31, 2025 | 55.26 Mn |
| Sep 30, 2025 | 41.51 Mn |
| Jun 30, 2025 | 45.23 Mn |
| Mar 31, 2025 | 53.38 Mn |
| Dec 31, 2024 | 58.90 Mn |
| Sep 30, 2024 | 69.39 Mn |
| Jun 30, 2024 | 76.61 Mn |
| Mar 31, 2024 | 85.44 Mn |
| Dec 31, 2023 | 94.20 Mn |
| Sep 30, 2023 | 103.06 Mn |
| Jun 30, 2023 | 112.61 Mn |
| Mar 31, 2023 | 122.10 Mn |
| Dec 31, 2022 | 134.05 Mn |
| Sep 30, 2022 | 148.33 Mn |
| Jun 30, 2022 | 161.71 Mn |
| Mar 31, 2022 | 178.83 Mn |
| Dec 31, 2021 | 202.47 Mn |
| Sep 30, 2021 | 207.94 Mn |